InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced a strategic equity investment and research collaboration with Sanofi. The agreement with Sanofi includes the right of first negotiation for InduPro’s bispecific PD-1 agonist program, which is currently in preclinical development for the treatment of autoimmune and inflammatory disorders..

InduPro公司是一家定义膜蛋白空间关系以创造治疗癌症和自身免疫疾病新疗法的生物技术公司，该公司今日宣布与赛诺菲达成战略股权融资及研究合作。根据与赛诺菲的协议，包含对InduPro双特异性PD-1激动剂项目的优先谈判权，该项目目前正在针对自身免疫和炎症性疾病的临床前开发阶段。

“We are thrilled to collaborate with Sanofi to advance toward the clinic our bispecific PD-1 agonist program. Sanofi’s know-how and global leadership position in autoimmune and inflammatory diseases make them the ideal partner to bring this exciting first-in-class molecule forward,” said Prakash Raman, Ph.D., Chief Executive Officer of InduPro.

“我们非常高兴与赛诺菲合作，推动我们的双特异性PD-1激动剂项目走向临床。赛诺菲在自身免疫和炎症疾病领域的专业知识和全球领导地位使他们成为推动这一令人兴奋的首创新药分子的理想合作伙伴，”InduPro首席执行官Prakash Raman博士表示。

“In addition, we welcome Sanofi’s strategic equity investment into InduPro, which further reinforces the strength of our collaboration.”.

“此外，我们欢迎赛诺菲对InduPro的战略股权投资，这进一步加强了我们合作的力量。”

Under the terms of the agreement, InduPro and Sanofi will collaborate on preclinical and IND-enabling research activities with funding from Sanofi, which will also make an undisclosed equity investment in InduPro.

根据协议条款，InduPro 和赛诺菲将合作进行临床前和新药临床试验申请（IND）所需的研究活动，赛诺菲将提供资金支持，并对 InduPro 进行数额未公开的股权投资。

InduPro therapeutically targets cell surface proteins in a variety of disease contexts by leveraging inherent or induced protein proximity. Through precise mapping of protein neighborhoods using its proprietary, high resolution proximity labeling technology, the Company is discovering novel co-target pairs that are highly selective for specific disease biology.

InduPro通过利用固有或诱导的蛋白质邻近性，在多种疾病环境中治疗性地靶向细胞表面蛋白。通过使用其专有的高分辨率邻近标记技术精确绘制蛋白质邻域，该公司正在发现对特定疾病生物学具有高度选择性的新型共靶标对。

Targeting these unique pairings via induced proximity provides a novel mechanism for influencing the cellular signaling pathways that are critical for impacting disease. InduPro’s approach relies on a unique discovery engine to generate potential first-in-class and best-in-class novel therapeutic candidates across multiple indications and modalities..

通过诱导接近来靶向这些独特的配对，为影响对疾病至关重要的细胞信号通路提供了一种新机制。InduPro 的方法依赖于一个独特的发现引擎，以在多种适应症和模式下生成潜在的首创和最佳新型治疗候选药物。

About InduPro

关于InduPro

InduPro is a biotechnology company defining and harnessing inherent and induced proximity biology to unlock next-generation therapeutics in cancer and autoimmune diseases. The Company develops therapeutics against novel, tumor-selective targets and co-target pairs using bispecific antibodies including antibody drug conjugates (ADCs) and T cell engagers (TCEs), fueling a robust pipeline of first- and best-in-class programs.

InduPro是一家生物技术公司，致力于定义和利用内在和诱导的邻近生物学，以开发癌症和自身免疫疾病领域的下一代疗法。该公司通过双特异性抗体，包括抗体药物偶联物（ADC）和T细胞接合器（TCE），针对新型肿瘤选择性靶点和共靶点对开发治疗药物，推动了一系列首创和同类最佳项目的发展。

To learn more, visit https://www.induprotx.com..

要了解更多信息，请访问 https://www.induprotx.com。

Source: induprotx.com

来源：induprotx.com